南华生物：拟收购慧泽医药51%股权，重组事项仍在推进

Core Viewpoint - The company announced plans to acquire a 51% stake in Huize Pharmaceutical from Chengzeneng and others, which will make Huize a subsidiary after the transaction is completed. This transaction is expected to constitute a major asset restructuring and does not involve related party transactions, issuance of shares, or changes in control [1]. Group 1 - The acquisition is scheduled for disclosure on August 12, 2025, and is currently in the process of due diligence [1]. - The exclusivity period has expired, and all parties are actively promoting the transaction [1]. - The restructuring is still ongoing and carries uncertainties as a formal agreement has not yet been signed [1].